Articles with "idh2" as a keyword



The role of mutant IDH1 and IDH2 inhibitors in the treatment of acute myeloid leukemia

Sign Up to like & get
recommendations!
Published in 2017 at "Annals of Hematology"

DOI: 10.1007/s00277-017-3161-0

Abstract: For decades, researchers have looked into the pathophysiology of acute myeloid leukemia (AML). With the advances in molecular techniques, the two-hit hypothesis was replaced by a multi-hit model, which also emphasizes the importance of aberrant… read more here.

Keywords: idh1 idh2; myeloid leukemia; idh2; acute myeloid ... See more keywords

Isocitrate dehydrogenase gene mutations and 2-hydroxyglutarate accumulation in esophageal squamous cell carcinoma

Sign Up to like & get
recommendations!
Published in 2018 at "Medical Oncology"

DOI: 10.1007/s12032-018-1229-x

Abstract: Isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) are key metabolic enzymes that convert isocitrate to α-ketoglutarate. Somatic point mutations in IDH1/2 confer a gain-of-function in cancer cells, resulting in overproduction of an oncometabolite, 2-hydroxyglutarate… read more here.

Keywords: esophageal squamous; idh1 idh2; isocitrate dehydrogenase; idh2 mutations ... See more keywords

APC/C CDH1 ubiquitinates IDH2 contributing to ROS increase in mitosis.

Sign Up to like & get
recommendations!
Published in 2021 at "Cellular signalling"

DOI: 10.1016/j.cellsig.2021.110087

Abstract: NADPH is a cofactor used by reactive oxygen species (ROS) scavenging enzymes to block ROS produced in cells. Recently, it was shown that in cancer cells, ROS progressively increases in tune to cell cycle leading… read more here.

Keywords: cdh1; mitosis; ros increase; apc cdh1 ... See more keywords

Association between Genetic Variations of Mitochondrial Isocitrate Dehydrogenase (IDH2) and Acute Myocardial Infarction.

Sign Up to like & get
recommendations!
Published in 2022 at "Gene"

DOI: 10.1016/j.gene.2022.146497

Abstract: PURPOSE Mitochondrial isocitrate dehydrogenase (IDH2) is a major contributor to cellular redox control. The aim of this study was to preliminary link IDH2 genetic variations to redox imbalance, atherogenesis and risk of acute myocardial infarction… read more here.

Keywords: genetic variations; dehydrogenase idh2; mitochondrial isocitrate; idh2 ... See more keywords

Loss of IDH1 and IDH2 in macrophages induces pathological phenotypes in cardiomyocytes

Sign Up to like & get
recommendations!
Published in 2024 at "European Heart Journal"

DOI: 10.1093/eurheartj/ehae666.3690

Abstract: The clonal expansion of hematopoietic stem cells can be induced by a variety of age-related somatic mutations, a phenomenon known as "clonal hematopoiesis of indeterminate potential" (CHIP). CHIP is associated with an increased incidence and… read more here.

Keywords: supernatants idh1; idh2; loss; idh1 idh2 ... See more keywords

IDH2 mutations are commonly associated with 1p/19q codeletion in diffuse adult gliomas.

Sign Up to like & get
recommendations!
Published in 2018 at "Neuro-oncology"

DOI: 10.1093/neuonc/noy014

Abstract: 716 IDH2 mutations are commonly associated with 1p/19q codeletion in diffuse adult gliomas Diffuse gliomas are classified according to the 2016 World Health Organization (WHO) Classification of Tumors of the Central Nervous System, 1 which… read more here.

Keywords: gliomas; idh2 mutant; 19q codeletion; idh2 ... See more keywords

MicroRNA 101 Attenuated NSCLC Proliferation through IDH2/HIFα Axis Suppression in the Warburg Effect

Sign Up to like & get
recommendations!
Published in 2022 at "Oxidative Medicine and Cellular Longevity"

DOI: 10.1155/2022/4938811

Abstract: Lung cancer is the most diagnosed and deadly cancer in China. MicroRNAs are small noncoding RNA gene products that exhibit multifunctional regulation in cancer cell progressions. MiR-101 loss was illustrated in about 29% of lung… read more here.

Keywords: idh2; warburg effect; 101 attenuated; mir 101 ... See more keywords

Abstract CT026: A first-in-human phase 1 study of LY3410738, a covalent inhibitor of mutant IDH, in advanced myeloid malignancies

Sign Up to like & get
recommendations!
Published in 2023 at "Cancer Research"

DOI: 10.1158/1538-7445.am2023-ct026

Abstract: Background: LY3410738 is a potent, selective, covalent, dual inhibitor of IDH1/2 mutations (IDH1/2m). LY3410738 binds covalently at a novel binding site, enabling continued potency in preclinical models in the setting of second site IDH resistance… read more here.

Keywords: inhibitor; idh2; prior venetoclax; venetoclax prior ... See more keywords

IDH2 inhibition enhances proteasome inhibitor responsiveness in hematological malignancies.

Sign Up to like & get
recommendations!
Published in 2019 at "Blood"

DOI: 10.1182/blood-2018-05-850826

Abstract: Proteasome inhibitors (PI) are extensively used for the therapy of multiple myeloma (MM) and mantle cell lymphoma. However, patients continuously relapse or are intrinsically resistant to this class of drugs. Here, to identify targets that… read more here.

Keywords: inhibitor; agi 6780; inhibition; inhibition enhances ... See more keywords
Photo from wikipedia

Real World Use of IDH2- Targeted Inhibitors in a Single Academic Medical Center Experience Since Enasidenib FDA-Approval

Sign Up to like & get
recommendations!
Published in 2019 at "Blood"

DOI: 10.1182/blood-2019-125135

Abstract: Background Enasidenib, a novel inhibitor of isocitrate dehydrogenase 2 (IDH2), offers targeted therapy to the ~12% of acute myeloid leukemia (AML) patients in which a recurrent IDH2 mutation exists. While currently only FDA approved for… read more here.

Keywords: clinical trial; fda approval; disease; idh2 ... See more keywords

Enasidenib vs conventional care in mutant-IDH2 relapsed/refractory acute myeloidleukemia: a randomized, phase 3 trial.

Sign Up to like & get
recommendations!
Published in 2022 at "Blood"

DOI: 10.1182/blood.2021014901

Abstract: This open-label, randomized, phase 3 trial (NCT02577406) compared enasidenib, an oral IDH2 inhibitor, with conventional care regimens (CCR) in patients aged ≥60 years with late-stage, mutant-IDH2 acute myeloid leukemia (AML) relapsed/refractory (R/R) to 2 or… read more here.

Keywords: phase trial; mutant idh2; randomized phase; idh2 ... See more keywords